A champagne inspired dual chain-responsive thrombolytic drug release platform based on black phosphorus nanosheets for accelerated thrombolysis
A champagne inspired dual chain-responsive thrombolytic drug release platform based on black phosphorus nanosheets for accelerated thrombolysis
复制标题
受香槟启发的基于黑磷纳米片的双链响应溶栓药物释放平台，用于加速溶栓
DOI：
10.1039/c9nh00344d
复制
发表时间：
2019-11-01
影响因子：
9.7
通讯作者：
Wang, Xiaolei
中科院分区：
文献类型：
--
作者：
Ding, Xingwei;Hong, Can;Wang, Xiaolei
面对溶栓药物血液循环时间短、给药剂量大、出血副作用大等临床难题，研制一种智能可控的溶栓药物纳米释药系统用于物理辅助溶栓具有重要意义。受Champagne链反应溶栓药物传递系统的启发，制备了uPA@黑磷纳米片-全氟正戊烷@介孔二氧化硅纳米颗粒（uPA@BPNs-PFP@MSNs）多功能平台。双链响应性溶栓药物递送平台首先通过使用近红外（NIR）激光照射（808 nm，0.2 W cm（-2））的黑磷纳米片的光热效应触发，随后加速溶栓药物释放并从材料的相变产生气泡。通过静电吸附法将该平台整合，并对该平台的体外溶栓、稳定性和细胞相容性进行了评价。建立小鼠急性颈静脉血栓形成模型，评价其溶栓作用、生物安全性和体内分布。鉴于这些结果，该平台具有潜在的应用，安全地提供溶栓药物，并在临床上以减少的药物剂量加速溶栓。
To face the clinical challenges related to thrombolytic drugs, such as short blood circulation time, the large dosage required and the side effects of bleeding, the fabrication of a smart controlled thrombolytic drug release nano-system for physical assistant thrombolysis would be very significant. Inspired by champagne, an integrated chain-responsive thrombolytic drug delivery system, uPA@black phosphorus nanosheets-perfluoro-n-pentane@mesoporous silica nanoparticles (uPA@BPNs-PFP@MSNs) was fabricated as a multifunctional platform. The dual chain-responsive thrombolytic drug delivery platform, is first triggered by the photothermic effect of the black phosphorus nanosheets using near-infrared (NIR) laser irradiation (808 nm, 0.2 W cm(-2)), followed by accelerated thrombolytic drug release and the generation of bubbles from the phase change of the material. This platform was integrated via electrostatic adsorption and the thrombolysis, stability and cytocompatibility in vitro were assessed. Additionally, a murine acute jugular vein thrombosis model was built to evaluate the thrombolysis, biosafety and distribution in vivo. In light of these results, the platform has potential applications for delivering thrombolytic drugs safely and accelerating thrombolysis with a reduced dose of drugs clinically.